# Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

> **NCT06819215** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang Yangli Pharmaceutical Technology Co., Ltd.** · enrollment: 188 (estimated)

## Conditions studied

- Cancer
- Neoplasms
- Neoplasms, Breast
- Tumor
- PARP
- Ovarian Neoplasms
- Prostatic Cancer
- Pancreatic Cancer
- Breast Cancer
- Biliary Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** VB15010

## Key facts

- **NCT ID:** NCT06819215
- **Lead sponsor:** Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819215, "Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06819215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*